SHINE

https://secureservercdn.net/198.71.233.129/w5m.a06.myftpupload.com/wp-content/uploads/2016/12/SHINE-Health-Illuminated-Logo-wt-tag-Color-PRESS-READY-PMSx2-copy-e1572637800234-300x107.pnghttps://secureservercdn.net/198.71.233.129/w5m.a06.myftpupload.com/wp-content/uploads/2019/11/SHINE-TRPS-and-ESFAS-Cabinets-300x200.png

Founded in 2010, SHINE is a development-stage company working toward becoming a manufacturer of radioisotopes for nuclear medicine. The SHINE system uses a patented, proprietary manufacturing process that offers major advantages over existing and proposed production technologies, as it does not require a nuclear reactor, uses less electricity, generates less waste and is compatible with the nation’s existing supply chain for molybdenum-99. In 2014, SHINE announced the execution of molybdenum-99 supply agreements with GE Healthcare and Lantheus Medical Imaging. In 2015, with the help of Argonne National Laboratory, GE Healthcare demonstrated SHINE molybdenum-99 can act as a drop-in replacement for reactor-based moly-99. In 2016, SHINE received regulatory approval to construct its facility from the Nuclear Regulatory Commission and signed a moly-99 supply agreement with HTA Co., Ltd., the largest Chinese distributor of radiopharmaceuticals.

SHINE PRESS RELEASE